DataMEDS AI, Inc. (MEDS) Guidance & Earnings Results
On 2026-05-19 DataMEDS AI, Inc. raised guidance: "Q2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MEDSDataMEDS AI, Inc.Follow MEDS — free
—
Price chart with a free account
- Market cap
- 6.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 19 May 26 | Raised | Q2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025 $0.486M |
DataMEDS AI, Inc. — questions
- What guidance did DataMEDS AI, Inc. give?
- On 2026-05-19: "Q2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025 $0.486M"
- When does DataMEDS AI, Inc. report earnings?
- DataMEDS AI, Inc.'s next earnings report is expected on 2026-11-18.
Every figure on this page comes from DataMEDS AI, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.